Moexipril is the generic equivalent of the Schwarz Pharma’s blood pressure drug, Univasc.
Israeli drug maker Teva (Nasdaq: TEVA) announced on Thursday that it received US FDA approval to market Moexipril HCl Tablets, in 7.5 mg and 15 mg dosages.
Moexipril is the generic equivalent of the Schwarz Pharma’s blood pressure drug, Univasc, which recorded about $70 million in annual sales.
This latest approval for Teva follows a March 24, 2003 summary judgment decision, which found that Teva's product did not infringe a patent asserted by Schwarz Pharma.
Teva said that as the first company to file to market a generic version, it was eligible for 180 days marketing exclusivity from the date of the summary judgement. Shipment of this product would begin immediately, the company added.
Teva’s Tel Aviv shares traded up 2.6% at NIS 215 on Sunday morning. The company’s Nasdaq stock closed on Friday at $47.67.
Published by Globes [online] - www.globes.co.il - on 11 May, 2003